Research study Program year 2025 Source: CMS Open Payments

T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease

Research payments

$3,792,866

544 payments

Through program year 2025, $3,792,866 in research payments was reported against T Dm1 Atezolizumab in High Risk Her2 Patients With Residual Disease, across 544 payments.

Paid by (largest first): Genentech, Inc.; F. Hoffmann-La Roche AG
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$903,425	147
2024	Research	$757,749	124
2023	Research	$1,136,607	150
2022	Research	$698,542	86
2021	Research	$296,544	37

Breakdown

Who paid Research payments · program years 2021–2025

Genentech, Inc. $3,792,027 542 payments
F. Hoffmann-La Roche AG $839 2 payments

Who received the money Research payments · program years 2021–2025

University Of Texas Health Science Ctr Financial Affairs Manager Organisation paid for research $505,558 55 payments
Qcca Network LLC Organisation paid for research $317,849 52 payments
Providence Health + Services Wa Providence Regional Medical Ctr Everett Organisation paid for research $310,263 51 payments
Clinical Trials Network Of Tennessee Organisation paid for research $197,346 29 payments
Toi Clinical Research LLC Organisation paid for research $181,941 44 payments
Kadlec Regional Medical Center Teaching hospital · WA $157,956 8 payments
Northwest Georgia Oncology Centers Pc Organisation paid for research $152,454 18 payments
University Of Iowa Hosp & Clinics Teaching hospital · IA $126,444 29 payments
The Valley Hospital Organisation paid for research $108,236 26 payments
Valley Hospital INC Organisation paid for research $105,702 12 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

5 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.